Infectious Disease
RSSArticles
-
Clinical Briefs
Topics: Metformin: Have we Been Overcautious in CKD?, Reduction in Prostate, and Doing the Right Thing for Acute Bronchitis in Healthy Adults: Antibiotics
-
Edoxaban Tablets (Savaysa™)
The third oral factor Xa inhibitor has been approved by the FDA. Edoxaban is the fourth target-specific oral anticoagulant (TSOA) to enter the market following dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). Edoxaban is manufactured by Tokyo-based Daiichi Sankyo Company and marketed by Daiichi Sankyo as Savaysa.
-
The Economic Burden of Undiagnosed Pre-diabetes
The economic burden of diagnosed and undiagnosed diabetes, gestational diabetes, and prediabetes has exceeded $322 billion.
-
Treatment of C. Difficile — Follow the Guidelines
ABSTRACT & COMMENTARY: The primary outcome was the occurrence of complications, including relapse within four weeks, surgery, and 30-day mortality.
-
Should Clinicians Discuss Resumption of Sexual Activity Following an Acute MI?
Although the U.S. and European cardiovascular society guidelines recommend that patients be counseled about resuming sexual activity after suffering an acute myocardial infarction (AMI), the actual demographics of sexual education post-myocardial infarction (MI) are unknown.
-
Can Answering a Phone Call Give You Cancer?
In the past decade, cellular phone usage has grown exponentially worldwide, and this use is prevalent in all age groups, including children.
-
Intracranial Hemorrhage Risk: Are Novel Oral Anticoagulants Better Than Warfarin?
Clinicians have commonly overestimated the risk of intracerebral hemorrhage (ICH) during anticoagulant therapy. Indeed, such misapprehensions have sometimes led to failure to employ warfarin (and probably other agents) when indicated for atrial fibrillation. There is little dispute that novel oral anticoagulants (apixiban, dabigatran, rivaroxaban) are simpler to use, since they do not require monitoring and are essentially free of food interactions. Clinical trials with novel oral anticoagulants (NOACs) have consistently documented that NOACs are associated with lesser risk of ICH, which is certainly a good thing … but how much of a good thing?
-
Colon Cancer Screening by Stool DNA Testing
Recent guidelines issued by the American Cancer Society and American Society of Gastroenterology recommend colonoscopy as the preferred screening method for colon cancer, but wisely include the philosophy, “The best colon cancer screening test is the test you can get done!” — reflecting the relative reticence shown by many Americans to undergo colonoscopy. CT colonography compares very favorably colonoscopy, yet many insurers are not willing to pay for it.
-
Long-term Payoff of Bariatric Surgery
The benefits of bariatric surgery are gaining new levels of respect as long-term evidence of favorable outcomes — other than cosmetic — continue to accrue. Indeed, in the population of obese diabetics, bariatric surgery is one of the only interventions documented to improve all-cause mortality.
-
Weighing the Harms and Benefits of E-cigarettes
So far, studies evaluating whether e-cigarettes are less harmful than traditional cigarettes remain mostly inconclusive.